Results 61 to 70 of about 5,563 (240)

A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia

, 2021
Purpose: Although considerable progress has been made with autologous T cell-based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity that is ...
Kater, Arnon P., Ruben, Jurjen M, de Gruijl, Tanja D, Kloosterman, J., de Gruijl, Tanja D., van der Vliet, Hans J, Lameris, R., Parren, Paul W. H. I., King, Lisa A., van der Vliet, Hans J., Parren, P.W.H.I., Vliet, H.J. van der, Ruben, Jurjen M., Kater, A.P., Ruben, J.M., Weerdt, I. de, Kloosterman, Jan, Boer, R. de, King, L.A., de Boer, Renate, King, Lisa A, Levin, M.D., Parren, Paul W H I, de Weerdt, Iris, Levin, Mark-David, Kater, Arnon P, Gruijl, T.D. de, Lameris, Roeland   +27 more
core   +1 more source

LILRB1 blockade enhances bispecific T cell engager antibody-induced tumor cell killing by effector CD8+ T cells [PDF]

, 2019
Elicitation of tumor cell killing by CD8+ T cells is an effective therapeutic approach for cancer. In addition to using immune checkpoint blockade to reinvigorate existing but unresponsive tumor-specific T cells, alternative therapeutic approaches have ...
Sewell, Andrew K., Yu, Xin, Ouyang, Wenjun, Kim, Aeryon, Driver, Ian, Zhang, Zemin, Han, Chia-Jung, Egen, Jackson G., Olow, Aleksandra   +8 more
core   +1 more source

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

, 2022
Poorly differentiated neuroendocrine carcinomas such as small-cell lung cancer (SCLC) have poor survival and high relapse rates. DLL3 is found on these carcinomas and has become a target of increasing interest in recent years.
Owonikoko, Taofeek K, Hamed, Zohra Oum\u27, Wermke, Martin, Gambardella, Valentina, Kuboki, Yasutoshi, Felip, Enriqueta, Liu, Meiruo, Morgensztern, Daniel, Studeny, Matus   +8 more
core   +1 more source

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

Advanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Yongjiang Zheng   +5 more
wiley   +1 more source

Epitope‐Resolved Digital SERS Profiling of Structurally Dynamic Antigens via a Multi‐Epitope Bispecific Antibody Framework

Advanced Science, EarlyView.
A multi‐epitope digital surface‐enhanced Raman spectroscopy framework enables epitope‐resolved immunoprofiling by integrating bispecific antibody fragments with spectrally encoded nanotags. This approach decouples binding events into independent digital channels, allowing structure‐aware antigen analysis.
Jing Wang, Quan Zhou, Kym Lowry, Christopher B. Howard, Matt Trau   +4 more
wiley   +1 more source

Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

Biomedicines, 2020
Oncolytic viruses (OVs) are potent anti-cancer biologics with a bright future, having substantial evidence of efficacy in patients with cancer. Bi- and tri-specific antibodies targeting tumor antigens and capable of activating T cell receptor signaling ...
Zong Sheng Guo, Michael T. Lotze, Zhi Zhu, Walter J. Storkus, Xiao-Tong Song   +4 more
doaj   +1 more source

Data_Sheet_1_Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.docx

, 2019
Bispecific T-cell engager antibodies (BiTE) have been explored as a means to recruit cytolytic T cells to kill tumor cells. The transferrin receptor (TfR) is highly expressed on the surface of rapidly proliferating tumor cells.
Zilong Guo (3332625), Guanxin Shen (124738), Qi He (384033), Huifen Zhu (125715), Mingpeng Fu (6865265), Liang Zhao (94728), Hongling Tang (6865271), Heli Li (6747758), Xiaoqi Zhou (104860), Yong He (115255), Xiaoran Zhou (6865268), Ping Lei (124737)   +11 more
core   +1 more source

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

Advanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou, Huiping He, Simin Xia, Xi Chen   +3 more
wiley   +1 more source

TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens for cancer immunotherapy

Signal Transduction and Targeted Therapy
T cell engager (TCE) immunotherapies have revolutionized the landscape of cancer treatment; however, their efficacy remains limited by the inaccessibility of intracellular tumor antigens.
Ziqiang Ding, Shuyang Sun, Xiaomei Yang, Xianing Huang, Xiaoqiong Hou, Shenxia Xie, Aiqun Liu, Xiaoling Lu   +7 more
doaj   +1 more source